Aromatase inhibitor strategies in metastatic breast cancer

References

• World Health OrganizationWorld Cancer ReportLyon, FranceWorld Health Organization, IARC Press2003
   Google Scholar
• American Cancer SocietyCancer Facts and Figures 20082008 Accessed April 7, 2009. Available from: http://www.cancer.org/
   Google Scholar
• LayfieldLJGuptaDMooneyEEAssessment of tissue estrogen and progesterone receptor levels: A survey of current practice, techniques, and quantitation methodsBreast J2000618919611348363
   PubMedGoogle Scholar
• FisherBCostantinoJPWickerhamDLTamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyJ Natl Cancer Inst2005971652166216288118
   PubMed Web of Science ®Google Scholar
• DowsettMCunninghamDCSteinRCDose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patientsCancer Res198949130613122917360
   PubMed Web of Science ®Google Scholar
• JonesALMacNeillFJacobsSThe influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patientsEur J Cancer199228A171217161389491
   PubMed Web of Science ®Google Scholar
• LonningPEGeislerJJohannessenDCPharmacokinetics and metabolism of formestane in breast cancer patientsJ Steroid Biochem Mol Biol200177394711358673
   PubMed Web of Science ®Google Scholar
• PerezEASafety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancerAnn Oncol200718Suppl 8viii26viii3517890211
   PubMed Web of Science ®Google Scholar
• FisherSAReidRLVan VugtDACasperRFA randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal womenFertil Steril20027828028512137863
   PubMed Web of Science ®Google Scholar
• DowsettMHaynesBPHormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifenJ Steroid Biochem Mol Biol20038625526314623519
   PubMed Web of Science ®Google Scholar
• BonneterreJThurlimannBRobertsonJFAnastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Clin Oncol2000183748375711078487
   PubMed Web of Science ®Google Scholar
• BonneterreJBuzdarANabholtzJMAnastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer2001922247225811745278
   PubMed Web of Science ®Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol2000183758376711078488
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYPhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol2003212101210912775735
   PubMed Web of Science ®Google Scholar
• ParidaensRTherassePDirixLFirst line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): A randomized phase III trial of the EORTC breast groupProc Am Soc Clin Oncol200422145515
   Google Scholar
• ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol2008264883489018794551
   PubMed Web of Science ®Google Scholar
• NabholtzJMBonneterreJBuzdarARobertsonJFThurlimannBAnastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety resultsEur J Cancer2003391684168912888362
   PubMed Web of Science ®Google Scholar
• MauriDPavlidisNPolyzosNPIoannidisJPSurvival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysisJ Natl Cancer Inst2006981285129116985247
   PubMed Web of Science ®Google Scholar
• ChiaSGradisharWMauriacLDouble-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol2008261664167018316794
   PubMed Web of Science ®Google Scholar
• OsborneCKPippenJJonesSEDouble-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trialJ Clin Oncol2002203386339512177098
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFRQuaresma AlbanoJFulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentJ Clin Oncol2002203396340312177099
   PubMed Web of Science ®Google Scholar
• BuzdarAUJonatWHowellAAnastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study GroupCancer199883114211529740079
   PubMed Web of Science ®Google Scholar
• BuzdarADoumaJDavidsonNPhase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetateJ Clin Oncol2001193357336611454883
   PubMed Web of Science ®Google Scholar
• KaufmannMBajettaEDirixLYExemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupJ Clin Oncol2000181399141110735887
   PubMed Web of Science ®Google Scholar
• FossatiRConfalonieriCTorriVCytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 womenJ Clin Oncol199816343934609779724
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med20053531673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med20053531659167216236737
   PubMed Web of Science ®Google Scholar
• CobleighMVogelCTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol1999172639264810561337
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol20022071972611821453
   PubMed Web of Science ®Google Scholar
• BaselgaJCarbonellXCastaneda-SotoNJPhase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly scheduleJ Clin Oncol2005232162217115800309
   PubMed Web of Science ®Google Scholar
• ArpinoGWiechmannLOsborneCKSchiffRCrosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistanceEndocr Rev20082921723318216219
   PubMed Web of Science ®Google Scholar
• MarcomPKIsaacsCHarrisLThe combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancersBreast Cancer Res Treat2007102434916897431
   PubMed Web of Science ®Google Scholar
• ClemensMKaufmanBMackeyJRTrastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the TAnDEM study2007 Breast Cancer Symposium: American Society of Clinical Oncology2007
   Google Scholar
• JohnstonSPegramMPressMLapatinib combined with letrozole vs letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 TrialSan Antonio, TXSan Antonio Breast Cancer Symposium2008
   Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med20073572666267618160686
   PubMed Web of Science ®Google Scholar
• TrainaTARugoHCaravelliJLetrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) [abstract]J Clin Oncol24suppl3050
   Google Scholar
• CristofanilliMValeroVMangalikAA phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) [abstract]J Clin Oncol200826suppl101218281677
   PubMed Web of Science ®Google Scholar
• SmithIEWalshGSkeneAA phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancerJ Clin Oncol2007253816382217679728
   PubMed Web of Science ®Google Scholar
• BonneterreJAnastrozole compared with tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer – survival analysesAnn Oncol2002134711863110
   PubMed Web of Science ®Google Scholar